1 / 8

Oblique Back-illumination Microscopy Jerome Mertz

Oblique Back-illumination Microscopy Jerome Mertz. June 15, 2012. Oblique Back-illumination Microscopy (OBM ) Breakthrough imaging allows DIC-like images in thick samples. 600μm field-of-view with 6.5μm resolution 240μm field-of-view with 2.5μm resolution

bunme
Download Presentation

Oblique Back-illumination Microscopy Jerome Mertz

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oblique Back-illumination MicroscopyJerome Mertz June 15, 2012

  2. Oblique Back-illumination Microscopy (OBM)Breakthrough imaging allows DIC-like images in thick samples • 600μm field-of-view with 6.5μm resolution • 240μm field-of-view with 2.5μm resolution • No labeling or contrast required • Video rate

  3. OBM offers superior imaging and high clinical impactin a simple, robust, and cost-effective platform Superior imaging capabilities with high clinical impact • Exquisite high resolution phase images (DIC-like) of in vivo tissue morphology • Simultaneous phase and amplitude microscopy with tissue imaging depth of 60-100μm • improves diagnostic imaging in thick tissue • applications in endoscopy • Works at video rate with a standard camera Simple, robust, cost effective, and safe • Add-on to current microscopes or endomicroscopes, with no moving parts • Noninvasive, no tissue labeling required • Illuminated using LEDs rather than expensive and unsafe lasers

  4. Both research and clinical applicationsare possible with OBM Research Applications • $3B US Microscope Market in 2011 with 6% CAGR through 20151 • Several Established Players: Leica, Carl Zeiss, Olympus, etc • 790 Potential Target Labs in US2 Clinical Applications3 • GI Endoscopy • > 10 MM Procedures / year • Colorectal, Gall, Esophageal • Blood flow analysis in plastic / reconstructive surgery • >1MM surgeries per year • Bladder imaging • Jon Groberg, Dane Leone, CFA, “Danaher: BEC is the key to continued success”, Macquarie (USA) Equities Research, 16 Aug 2011 • Source: http://www.lltechimaging.com/ • Source: Mauna Kea Investor Presentation, published June 2011

  5. GI screening offers a compelling opportunity for OBM Colorectal Screenings Barrett’s Esophagus • 3.1 MM colorectal screenings in US annually • High percentage of biopsied polyps are benign • Strong market opportunity for technologies that aid in biopsy site determination • > 1 MM screenings in US annually • American Gastroenterological Assoc. recently increased recommended screening schedule for high risk patients • 85% mortality rate for Esophageal cancer (BE increases cancer risk)

  6. OBM combines high resolutionimaging with tissue depth, wide field-of-view and video capabilities Technology OBM OCT1 Confocal fluorescenceEndomicroscopy2 Lateral Resolution (μm) 2.5 / 6.5 3.5 1 - 3.5 Axial Resolution (μm) 6 1.8 3 - 8 Imaging Depth (μm) 0 - 80 100 5 - 100 Field of View (μm) 240 / 600 1.5 x 1.5 mm (scanning) 240 / 400 Frame Rate (Hz) 17.5 1 12 (200 optional) 1. Optical Coherence Tomography – data points based on lltech Light-CT 2. Confocal Laser Endomicroscopy – data points based on various CellVizio models

  7. Rigid endoscope market exceeds $500M annually; Karl Storz is the market leader • Market Size (2010): • $529M WW, 4% CAGR • $176M US, 4% CAGR • Laparoscopic, Hysteroscopicuses Source: “Rigid Endoscopes - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017”, Global Data, 31 May 2011

  8. In vivo Imaging Technologies 1. Thomson Reuters Streetevents, “Edited Transcript: GTHP.OB-Q4 2011 Guided Therapeutics Inc. Earnings Conference Call”, 29 March 2012, 3:00PM GMT 2. Source: Mauna Kea Investor Presentation, published June 2011 3. Josh Jennings, M.D., Denis Kelleher, Ian Sanderson, Doug Schenkel, “Mela Sciences – Initiating with Outperform (1)”, Cowen and Company, 23 May 2012 4. Matt Miksic, SachinKulharni, Young Li, “ Novadaq: Overweight”, PiperJaffray, Company Note, 16 April 2012

More Related